Prothena Corporation PLC (NASDAQ:PRTA) – Investment analysts at Jefferies Group dropped their Q3 2017 earnings per share estimates for shares of Prothena Corporation PLC in a research report issued to clients and investors on Tuesday. Jefferies Group analyst M. Yee now forecasts that the biotechnology company will post earnings of ($1.54) per share for the quarter, down from their prior forecast of ($1.48). Jefferies Group currently has a “Buy” rating and a $100.00 target price on the stock. Jefferies Group also issued estimates for Prothena Corporation PLC’s Q4 2017 earnings at ($1.77) EPS, FY2017 earnings at ($4.80) EPS and FY2018 earnings at ($6.82) EPS.

Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.43. The business had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. Prothena Corporation PLC had a negative return on equity of 34.50% and a negative net margin of 527.56%. Prothena Corporation PLC’s quarterly revenue was up 7951.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.18) earnings per share.

TRADEMARK VIOLATION NOTICE: “Q3 2017 EPS Estimates for Prothena Corporation PLC Decreased by Analyst (PRTA)” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/11/q3-2017-eps-estimates-for-prothena-corporation-plc-decreased-by-analyst-prta.html.

Other equities analysts have also issued research reports about the company. BidaskClub lowered Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research upgraded Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $59.00 target price on the stock in a research note on Tuesday, April 18th. Oppenheimer Holdings, Inc. set a $70.00 target price on Prothena Corporation PLC and gave the stock a “buy” rating in a research note on Thursday, May 11th. BTIG Research started coverage on Prothena Corporation PLC in a research note on Friday, May 19th. They set a “buy” rating and a $80.00 target price on the stock. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Prothena Corporation PLC in a research note on Tuesday, May 16th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $76.45.

Shares of Prothena Corporation PLC (NASDAQ:PRTA) opened at 55.64 on Friday. Prothena Corporation PLC has a 52-week low of $40.58 and a 52-week high of $69.53. The stock’s 50 day moving average price is $60.52 and its 200-day moving average price is $54.85. The company’s market capitalization is $2.12 billion.

In other Prothena Corporation PLC news, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now owns 6,345 shares in the company, valued at approximately $368,707.95. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at approximately $324,450. The disclosure for this sale can be found here. 3.10% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Amalgamated Bank raised its position in Prothena Corporation PLC by 11.2% in the second quarter. Amalgamated Bank now owns 4,731 shares of the biotechnology company’s stock worth $256,000 after buying an additional 476 shares during the period. BlackRock Inc. raised its position in Prothena Corporation PLC by 7.8% in the second quarter. BlackRock Inc. now owns 2,947,512 shares of the biotechnology company’s stock worth $159,519,000 after buying an additional 213,578 shares during the period. Nationwide Fund Advisors raised its position in Prothena Corporation PLC by 0.9% in the second quarter. Nationwide Fund Advisors now owns 46,504 shares of the biotechnology company’s stock worth $2,517,000 after buying an additional 407 shares during the period. TIAA CREF Investment Management LLC raised its position in Prothena Corporation PLC by 8.3% in the second quarter. TIAA CREF Investment Management LLC now owns 120,603 shares of the biotechnology company’s stock worth $6,527,000 after buying an additional 9,217 shares during the period. Finally, Alliancebernstein L.P. raised its position in Prothena Corporation PLC by 6.8% in the second quarter. Alliancebernstein L.P. now owns 895,759 shares of the biotechnology company’s stock worth $48,478,000 after buying an additional 57,002 shares during the period.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Earnings History and Estimates for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.